Tesamorelin Peptide For Sale
Buy Tesamorelin peptide: 2mg, 5mg, 10mg, 20mg, 30mg or 100mg listed purchase quantities. Compare live prices across 13 listed vendors with real cost per mg, recorded COA availability and discount codes.
Buy Tesamorelin peptide starting at $25.00/purchase from 13 listed vendors. Compare 2mg, 5mg, 10mg, 20mg, 30mg and 100mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).
How much does Tesamorelin cost per month?
An illustrative Tesamorelin cost model works out to about $97.41 per month: Modified Aminos's listed 20 mg purchase quantity at $89.99 with code WPA, divided into 1 mg amounts 5x weekly. This quantity provides 20.0 nominal portions — about 4.0 weeks at the selected cadence, before preparation losses or stability limits — for roughly $22.50 per week or $97.41 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 12,308 calculator runs; overall cadence comes from 5,455 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About Tesamorelin
FDA-approvedAlso known as: Egrifta · TH9507Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog most often sourced for research into visceral-fat reduction and the GH/IGF-1 axis. It is the same molecule sold as the FDA-approved drug Egrifta, and ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
What to check before you buy Tesamorelin:
- A third-party COA showing ≥98–99% purity by HPLC plus mass-spec confirmation of the 44-amino-acid sequence — not just an in-house "lab tested" badge.
- A COA dated within the last 6–12 months that matches the exact vial size and batch you are buying.
- Accurate vial fill: a 10mg label should assay close to 10mg. Under-filled or mislabeled vials are a common failure mode, and they throw off every reconstitution calculation.
The pivotal Phase 3 trials (Falutz et al., NEJM 2007; Stanley et al., JAMA 2014) demonstrated ~15–18% reductions in visceral adipose tissue at 26 weeks in HIV-associated lipodystrophy.[2] Ongoing investigator-initiated work has extended tesamorelin into non-HIV NAFLD/MASLD populations.[3]
Regulatory: FDA-approved as Egrifta (HIV-associated lipodystrophy). Off-label and research-grade use are outside the labeled indication.
Tesamorelin: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how Tesamorelin works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
Tesamorelin is a 44-amino-acid synthetic analog of human growth-hormone-releasing hormone (GHRH) with a hexenoyl (trans-3-hexenoic acid) group attached to the N-terminus.[1][6] That single modification resists cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades native GHRH within minutes, and extends the circulating half-life to roughly 26–38 minutes after subcutaneous injection — long enough to drive a clinically useful pituitary GH pulse but short enough to preserve the body's own pulsatile GH rhythm.[6][7] The molecule binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of the next endogenous GH pulse rather than producing a sustained GH elevation, which is mechanistically different from recombinant human GH (rhGH) replacement.[7] Daily 2 mg subcutaneous dosing elevates IGF-1 into the normal-to-upper-normal physiological range over the first weeks of treatment and produces the visceral-adipose-tissue (VAT) reductions documented in the Phase 3 program.[2][5] Hypothalamic somatostatin feedback remains intact, which is the framing for the lower incidence of supraphysiologic IGF-1 excursions relative to rhGH at clinically effective doses.[7] Tesamorelin does not act on appetite or gastric emptying — the VAT-loss mechanism is mediated through GH-driven lipolysis in visceral adipocytes, not through reduced food intake.[5][7]
Active research areas
- HIV-associated lipodystrophy (labelled indication)The pivotal Phase 3 program (Falutz et al., NEJM 2007 and the 52-week extension in AIDS 2008) established a ~15–18% reduction in visceral adipose tissue at 26 weeks in HIV-infected adults with central fat accumulation, with durability through one year.[2][4] This is the basis for the 2010 FDA approval of Egrifta and the 2019 reformulation as Egrifta SV.[1][6]
- NAFLD / MASH in HIVStanley et al. (Lancet HIV 2019; JAMA 2014) reported that tesamorelin reduces intrahepatic lipid content and slows fibrosis progression in HIV-infected adults with hepatic steatosis, with the JAMA trial showing meaningful absolute reductions in liver fat fraction at 26 weeks.[3][5] These findings have motivated MGH-led work extending tesamorelin into non-HIV NAFLD populations (NCT03375788).[8]
- Muscle composition and intramyocellular lipidA substudy from the lipodystrophy program reported that tesamorelin decreased intramuscular fat and increased muscle area at 26 weeks, suggesting the GH/IGF-1 axis effect extends to skeletal-muscle composition beyond simple VAT reduction.[9] Whether this translates into improvements in physical function in older non-HIV adults is an open investigator-initiated question.[7]
- Mild cognitive impairment and cognitive ageingInvestigator-initiated work has explored whether the pulsatile GH and IGF-1 elevation produced by tesamorelin yields measurable cognitive benefit in older adults and people with mild cognitive impairment, on the rationale that the GH–IGF-1 axis declines with age and IGF-1 has documented effects on hippocampal function.[7] Evidence to date is preliminary and not Phase 3 — no registered Phase 3 cognition outcome trial has been disclosed.
- Regulatory statusTesamorelin is FDA-approved as Egrifta SV solely for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.[1][6] All other use — including off-label use in non-HIV NAFLD/MASH, body-composition, and longevity protocols — is outside the labelled indication, regardless of whether the material is dispensed through a pharmacy or sourced as research-grade peptide.
Open questions & leading hypotheses (3)
- Hypothesis: Tesamorelin produces meaningful VAT and hepatic-fat reductions in non-HIV adults with central obesity or NAFLD.Evidence: The Phase 3 lipodystrophy program and the Stanley JAMA 2014 trial established the mechanism (GHRH-receptor-mediated pulsatile GH release driving visceral-adipocyte lipolysis) and produced clean VAT and liver-fat reductions in the HIV population.[2][5] The MGH-led non-HIV NAFLD trial (NCT03375788) is testing whether the effect generalises.[8] Counter-evidence: the HIV lipodystrophy population has a distinct visceral-adipose phenotype driven by antiretroviral therapy, and Phase 3 efficacy in that group does not automatically transfer to age-related or obesity-driven NAFLD; published non-HIV efficacy data are still limited.
- Hypothesis: Preserving pulsatile GH release is meaningfully safer or more physiologic than recombinant hGH replacement at clinically equivalent doses.Evidence: The GHRH-analog framing is that hypothalamic somatostatin feedback remains intact under tesamorelin, limiting supraphysiologic IGF-1 excursions and the associated long-term safety concerns of rhGH.[7] The labelled dosing band targets IGF-1 in the normal-to-upper-normal range, and the 52-week extension data did not show signal-out-of-band IGF-1 elevations at 2 mg/day.[4] Counter-evidence: no head-to-head trial against rhGH has been run at clinically equivalent IGF-1 exposures, and the long-term oncology and glucose-tolerance safety profile of GHRH-analog therapy outside the HIV lipodystrophy population has not been characterised in any Phase 3 trial.
- Hypothesis: Tesamorelin produces clinically meaningful cognitive benefit in older adults beyond what would be expected from improved sleep or body composition.Evidence: Small investigator-initiated studies in older adults and mild cognitive impairment have reported domain-specific cognitive signals tracking IGF-1 elevation,[7] motivating continued interest. Counter-evidence: no Phase 3 cognition outcome trial has been registered, the effect sizes seen so far are modest, and the cohorts have been too small to separate cognitive benefit from secondary effects on sleep, mood, or body composition.
What community users report
Anecdotal — not controlled-trial evidence
Across r/Peptides and r/PeptideAdmin, users running research-grade or compounded tesamorelin most often describe daily 1–2 mg subcutaneous protocols taken before bed on an empty stomach, with anecdotal reports of measurable waist-circumference reduction over 8–16 weeks and improved sleep depth within the first one to two weeks.[10][11] Many threads explicitly choose tesamorelin over CJC/ipamorelin stacks on the rationale that the molecule has a Phase 3 evidence base for visceral fat specifically, and over rhGH on the rationale that pulsatile GH release is closer to physiologic. Commonly reported side effects include water retention, joint stiffness, transient injection-site reactions, and worsened fasting glucose during the first month — all consistent with the documented GH/IGF-1 elevation.[2][4] A subset reports no measurable VAT change, often attributed to inconsistent dosing timing or short cycle length. **These reports are anecdotal and have not been validated in controlled trials outside the FDA-approved HIV-associated lipodystrophy indication.** They are useful for understanding what people who have already chosen to use off-label tesamorelin are experiencing, but they do not establish that any specific dose, schedule, or duration is safe or effective in non-HIV populations.
Sources & references (11)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]FDA approval letter, Egrifta (tesamorelin), November 2010 link
- [2]Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM 2007;357:2359–2370. · PMID: 18057338 link
- [3]Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6:e821–e830. · PMID: 31611038 link
- [4]Falutz J et al. Long-term safety and effects of tesamorelin, a GHRH analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22:1719–1728 — 52-week safety/efficacy extension confirming durability and safety in the lipodystrophy population. · PMID: 18690166 link
- [5]Stanley TL et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014;312:380–389 — JAMA trial that established the visceral and hepatic fat-reduction signal in HIV-associated lipodystrophy. · PMID: 25038357 link
- [6]EMD Serono / Theratechnologies prescribing information — Egrifta SV (tesamorelin for injection), current US Package Insert. link
- [7]Baker JV et al. Effects of growth hormone–releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies — review of GHRH-analog mechanism and lipodystrophy data. J Clin Endocrinol Metab 2017;102:1340–1349. · PMID: 28323942 link
- [8]ClinicalTrials.gov: NCT03375788 — Tesamorelin Effects on Liver Fat and Histology in NAFLD/NASH (Stanley TL, MGH). link
- [9]Adrian S, Scherzinger A, Sanyal A et al. The growth hormone–releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging 2019;8:154–159 — muscle-composition substudy from the lipodystrophy program. · PMID: 31237318 link
- [10]Community report — r/Peptides tesamorelin protocol and visceral-fat experience threads (subreddit), accessed May 2026. link
- [11]Community report — r/PeptideAdmin tesamorelin off-label dosing discussions (subreddit), accessed May 2026. link
What Tesamorelin Costs Right Now
WPA currently tracks Tesamorelin from 13 distinct vendors across 20 separate Tesamorelin listings. In-stock Tesamorelin vials run from $25 to $629.99 — a 25.2x spread for the same compound. Ascension Peptides holds the lowest sticker price at $25. Normalized to milligrams, Tesamorelin costs $4.50/mg to $12.58/mg on this page. The best per-milligram value is the listed 20 mg purchase quantity from Modified Aminos.
Tesamorelin is stocked in 6 sizes: 100 mg listed quantity; vial count not recorded; 10 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded; 2 mg listed quantity; vial count not recorded; 30 mg listed quantity; vial count not recorded; 5 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the Tesamorelin listings WPA tracks are: Modified Aminos — 20mg at $89.99 ($4.50/mg), COA purity 99.00%; Felix Chem — 10mg at $49.49 ($4.95/mg), COA purity 99.86%; Ascension Peptides — 5mg at $25 ($5.00/mg), COA purity 99.70%; Peptira — 30mg at $160.65 ($5.36/mg), COA purity 99.88%; Modified Aminos — 10mg at $53.99 ($5.40/mg), COA purity 99.00%.
Tesamorelin COA Coverage Across Tracked Vendors
20 of the 20 tracked Tesamorelin listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 20 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 97.74% to 99.99%. 18 listings record more Tesamorelin in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 10/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Tesamorelin offer. WPA's listing fields do not establish that a report was independently verified.
Tesamorelin Calculator Input Observations
In lifetime Tesamorelin calculator inputs, 1mg is the most frequent entered amount (4,192 of 12,308 runs). Separately, 5x/week is the most frequent overall cadence (1,181 of 5,455 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1mg, 5x/week is most frequent (471 of 2,151 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 100 mg of listed product divided by 1 mg gives roughly 100 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
Tesamorelin Discount Codes
20 of the 20 tracked Tesamorelin listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About Tesamorelin
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog most often sourced for research into visceral-fat reduction and the GH/IGF-1 axis. It is the same molecule sold as the FDA-approved drug Egrifta, and ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Tesamorelin is tracked under the Weight Loss category on WPA. Its reported half-life is ~26–38 min. Calculator inputs do not establish why a cadence was selected or validate a protocol. FDA-approved as Egrifta (HIV-associated lipodystrophy).
How to Read the Tesamorelin Comparison
- Price per milligram — Every Tesamorelin listing is normalized to $4.50/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 20 Tesamorelin listings are marked for COA availability, and 20 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The Tesamorelin comparison includes 2mg, 5mg, 10mg, 20mg, 30mg, and 100mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each Tesamorelin listing, refreshed on a recurring basis.
Frequently Asked Questions: Tesamorelin
Is it legal and safe to buy Tesamorelin for research?
In the US, Tesamorelin is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Tesamorelin has an FDA-approved prescription form for HIV-associated lipodystrophy; the research-grade listings here are not that approved product. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 20 Tesamorelin listings from 13 vendors.
How do I verify a Tesamorelin COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific Tesamorelin batch. Check that the report identifies the compound (actually tesamorelin, not a cheaper GHRH analog like sermorelin or CJC-1295), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Tesamorelin specifically, 20 of 20 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 20 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 10/26.
Which Tesamorelin vendor should I pick?
There's no single "best" Tesamorelin vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. Tesamorelin is sensitive to handling and reconstitution, so a recent COA and high assayed purity matter more than shaving a dollar off the price. 13 vendors currently carry Tesamorelin, and Modified Aminos holds the best true value at $4.50/mg on the 20 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does Tesamorelin cost — and how do I know I'm not overpaying?
Judge Tesamorelin by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. Compare the displayed nominal purchase quantities and package composition, not an assumed 10 mg single vial. Tracked Tesamorelin listings currently run $4.50/mg to $12.58/mg across 2mg, 5mg, 10mg, 20mg, 30mg, 100mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much Tesamorelin do I need for one full cycle?
In lifetime Tesamorelin calculator inputs, 1mg is the most frequent entered amount (4,192 of 12,308 runs). Separately, 5x/week is the most frequent overall cadence (1,181 of 5,455 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 1mg, 5x/week is most frequent (471 of 2,151 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 100 mg purchase quantity by 1 mg gives roughly 100 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for Tesamorelin?
Participating Tesamorelin vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 20 of the 20 tracked Tesamorelin listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Where can I compare Tesamorelin prices and listing details?
This comparison shows 20 tracked listings for Tesamorelin in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.